Our study indicates that despite the increasing use of afatinib as first-line TKI for EGFR mutant, late-stage adenocarcinoma patients, afatinib use was not associated with longer OS than were first-generation TKIs. The gene discussed is EGFR; the disease is adenocarcinoma.